144 related articles for article (PubMed ID: 20653979)
1. Price regulation, new entry, and information shock on pharmaceutical market in Taiwan: a nationwide data-based study from 2001 to 2004.
Hsiao FY; Tsai YW; Huang WF
BMC Health Serv Res; 2010 Jul; 10():218. PubMed ID: 20653979
[TBL] [Abstract][Full Text] [Related]
2. The influences of Taiwan's generic grouping price policy on drug prices and expenditures: evidence from analysing the consumption of the three most-used classes of cardiovascular drugs.
Chen CL; Chen L; Yang WC
BMC Public Health; 2008 Apr; 8():118. PubMed ID: 18405385
[TBL] [Abstract][Full Text] [Related]
3. Drugs cheaper than threepenny: the market of extremely low-priced drugs within the National Health Insurance in Taiwan.
Wang BR; Chou CL; Hsu CC; Chou YC; Chen TJ; Chou LF
ScientificWorldJournal; 2014; 2014():234941. PubMed ID: 24719568
[TBL] [Abstract][Full Text] [Related]
4. Impacts of drug reimbursement reductions on utilization and expenditures of oral antidiabetic medications in Taiwan: an interrupted time series study.
Hsu JC; Lu CY; Wagner AK; Chan KA; Lai MS; Ross-Degnan D
Health Policy; 2014 Jun; 116(2-3):196-205. PubMed ID: 24314624
[TBL] [Abstract][Full Text] [Related]
5. Changes in physicians' practice of prescribing cyclooxygenase-2 inhibitor after market withdrawal of rofecoxib: a retrospective study of physician-patient pairs in Taiwan.
Hsiao FY; Tsai YW; Huang WF
Clin Ther; 2009 Nov; 31(11):2618-27. PubMed ID: 20110006
[TBL] [Abstract][Full Text] [Related]
6. Decreasing utilization and increasing prices of brand-name oral contraceptive pills: Implications to societal costs and market competition.
Zhang JX
PLoS One; 2020; 15(6):e0234463. PubMed ID: 32525965
[TBL] [Abstract][Full Text] [Related]
7. The impact of price-cap regulations on market entry by generic pharmaceutical firms.
Zhang W; Sun H; Guh D; Anis AH
Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):231-238. PubMed ID: 27936981
[TBL] [Abstract][Full Text] [Related]
8. Effects of drug price reduction and prescribing restrictions on expenditures and utilisation of antihypertensive drugs in Korea.
Yoo KB; Lee SG; Park S; Kim TH; Ahn J; Cho MH; Park EC
BMJ Open; 2015 Jul; 5(7):e006940. PubMed ID: 26179644
[TBL] [Abstract][Full Text] [Related]
9. The impact of reference pricing of nonsteroidal anti-inflammatory agents on the use and costs of analgesic drugs.
Grootendorst PV; Marshall JK; Holbrook AM; Dolovich LR; O'Brien BJ; Levy AR
Health Serv Res; 2005 Oct; 40(5 Pt 1):1297-317. PubMed ID: 16174135
[TBL] [Abstract][Full Text] [Related]
10. Factors Affecting Usage Levels and Trends of Innovative Oncology Drugs Upon and After Reimbursement Under Taiwan National Health Insurance: Interrupted Time Series Analysis.
Liao KH; Ko BS; Chen LK; Hsiao FY
Clin Transl Sci; 2020 Nov; 13(6):1288-1297. PubMed ID: 32583962
[TBL] [Abstract][Full Text] [Related]
11. Examining product risk in context. Market withdrawal of zomepirac as a case study.
Ross-Degnan D; Soumerai SB; Fortess EE; Gurwitz JH
JAMA; 1993 Oct; 270(16):1937-42. PubMed ID: 8411550
[TBL] [Abstract][Full Text] [Related]
12. Effects of a price cut reform on the cost and utilization of antidiabetic drugs in Korea: a national health insurance database study.
Suh HS; Kim JA; Lee IH
BMC Health Serv Res; 2018 Jun; 18(1):429. PubMed ID: 29879966
[TBL] [Abstract][Full Text] [Related]
13. Market uptake of biologic and small-molecule--targeted oncology drugs in Europe.
Obradovic M; Mrhar A; Kos M
Clin Ther; 2009 Dec; 31(12):2940-52. PubMed ID: 20110034
[TBL] [Abstract][Full Text] [Related]
14. Pharmaceutical policy in the Netherlands: from price regulation towards managed competition.
Boonen LH; van der Geest SA; Schut FT; Varkevisser M
Adv Health Econ Health Serv Res; 2010; 22():53-76. PubMed ID: 20575228
[TBL] [Abstract][Full Text] [Related]
15. European healthcare policies for controlling drug expenditure.
Ess SM; Schneeweiss S; Szucs TD
Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
[TBL] [Abstract][Full Text] [Related]
16. Adoption of pharmaceutical innovation and the growth of drug expenditure in Taiwan: is it cost effective?
Hsieh CR; Sloan FA
Value Health; 2008; 11(2):334-44. PubMed ID: 18380646
[TBL] [Abstract][Full Text] [Related]
17. Does price regulation affect atorvastatin sales in India? An impact assessment through interrupted time series analysis.
Selvaraj S; Farooqui HH; Mehta A
BMJ Open; 2019 Jan; 9(1):e024200. PubMed ID: 30679294
[TBL] [Abstract][Full Text] [Related]
18. Impacts of cost containment strategies on pharmaceutical expenditures of the National Health Insurance in Taiwan, 1996-2003.
Lee YC; Yang MC; Huang YT; Liu CH; Chen SB
Pharmacoeconomics; 2006; 24(9):891-902. PubMed ID: 16942123
[TBL] [Abstract][Full Text] [Related]
19. Use of cognitive enhancers and associated medical care costs among patients with dementia: a nationwide study in Taiwan.
Ku LJ; Pai MC
Int Psychogeriatr; 2014 May; 26(5):795-804. PubMed ID: 24429098
[TBL] [Abstract][Full Text] [Related]
20. Price regulation and generic competition in the pharmaceutical market.
Dalen DM; Strøm S; Haabeth T
Eur J Health Econ; 2006 Sep; 7(3):208-14. PubMed ID: 16841230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
